Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP

"Long-term eltrombopag demonstrated efficacy in restoring platelet counts and decreasing risk of bleeding in patients with chronic/persistent immune thrombocytopenia (ITP) lasting more than 6 months, according to a study published in Blood.

Previous studies demonstrated that eltrombopag treatment for 6 months or less effectively increased platelet counts and reduced bleeding in patients with chronic ITP. The purpose of this analysis was to evaluate the safety and efficacy of long term therapy with eltrombopag."

- By James Nam, PharmD. Photo courtesy OncologyNurseAdvisor.com.

Read More


back to top
Charity Navigator
GuideStar Seal
NORD Member Badge
THSNA logo
THSNA Summit 2024
April 3-6th